ANI Pharmaceuticals (ANIP)

[silvr_surfr]

That's the only logical explanation. Well, it works in Art's favor to accrue options at a low strike price before some future big bang.

Just for fun, if Cold Genesys were bought for $2B with a $300M annual revenue stream, the benefit to ANIP shareholders would be:

* about $32/share one time payment (assuming 19% minority stake)
* about $15M in annual royalty income (assuming 5% royalty) or $1.25/share - a 30% increase vs 2017 adjusted non-GAAP diluted earnings per share